Who Owns SAB Biotherapeutics Stock?
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 75.39%
- Held by insiders
- 0.71%
- Institutional holders
- 112
- Institutions 75.4%
- Insiders 0.7%
- Public and other 23.9%
Who owns SAB Biotherapeutics stock?
Institutional investors own about 75.4% of SAB Biotherapeutics's shares, spread across 112 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.71% of SABS.
The largest institutional holders are Caligan Partners, LP (8.76%), Vivo Capital, LLC (8.02%) and Perceptive Advisors Llc (7.28%). Together, the top 10 institutions control 52.9% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their SABS positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of SABS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Caligan Partners, LP | 7.97M | 8.76% | 0.0% |
| Vivo Capital, LLC | 7.30M | 8.02% | -36.1% |
| Perceptive Advisors Llc | 6.63M | 7.28% | +3.0% |
| Adage Capital Partners GP L.L.C. | 6.41M | 7.04% | +88.1% |
| RA Capital Management, L.P. | 4.40M | 4.84% | 0.0% |
| Balyasny Asset Management LP | 3.76M | 4.13% | 0.0% |
| Blackrock Inc. | 3.07M | 3.37% | +917.5% |
| Vanguard Capital Management LLC | 2.97M | 3.27% | +19.2% |
| Commodore Capital Lp | 2.87M | 3.15% | -34.8% |
| Millennium Management Llc | 2.75M | 3.02% | -9.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of SABS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.26M | 2.48% |
| iShares Trust-iShares Russell 2000 ETF | 1.04M | 1.14% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 647.89K | 0.71% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 473.87K | 0.52% |
| iShares Trust-iShares Russell 2000 Value ETF | 380.75K | 0.42% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 278.65K | 0.31% |
| iShares Trust-iShares Micro-Cap ETF | 148.52K | 0.16% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 125.27K | 0.14% |
| American Century ETF Trust-Avantis U.S. Small Cap Equity ETF | 107.09K | 0.12% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 105.68K | 0.12% |
Frequently asked questions
Who is the largest shareholder of SAB Biotherapeutics?
Caligan Partners, LP is the largest institutional shareholder of SABS, owning 8.76% of shares outstanding (7.97M shares) as of its latest 13F filing.
What percentage of SAB Biotherapeutics is owned by institutions?
Institutions own about 75.4% of SABS shares and 75.9% of the public float.
How much of SAB Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 0.71% of SABS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.